Hematopoietic and Lymphoid Cell NeoplasmNCT04196972
Telementoring Intervention (ECHO) for the Transformation of Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in Diagnostic Imaging Clinicians
A study testing Communication Intervention, Questionnaire Administration and Waiting List in people with Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
This trial studies how well the Extension for Community Healthcare Outcomes (ECHO) telementoring intervention works in transforming professional engagement, practice efficiency, and community building through team meetings in diagnostic imaging clinicians. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- What is being tested?
- Communication Intervention, Questionnaire Administration and Waiting List
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- 16 Aug 2020to 31 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Faculty must be diagnostic imaging clinicians with a primary appointment in the Division of Diagnostic Imaging at MD Anderson
Who cannot join
- Faculty that have an official leadership role (Division Head or Department Chair)
- Faculty that have previously participated in any previous live ECHO clinic or ECHO activity
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Transforming Professional Engagement, Practice Efficiency, and Community Building Through Team Meetings in a Telementoring Environment
This trial studies how well the Extension for Community Healthcare Outcomes (ECHO) telementoring intervention works in transforming professional engagement, practice efficiency, and community building through team meetings in diagnostic imaging clinicians. This study may help researchers learn more about the potential benefits of a model for team meetings aimed at bringing physicians together from multiple practice locations when few opportunities exist for meaningful, collegial interactions. It may also help diagnostic imaging clinicians engage more effectively with colleagues at distant sites and become more engaged with their work.
Read the detailed description
PRIMARY OBJECTIVE:
- To determine the feasibility of the proposed anti-burnout intervention for faculty at MD Anderson, defined as at least 35/50 of participants each attending at least 9 out of 13 sessions.
SECONDARY OBJECTIVES:
- To explore any changes in burnout, measured by the Maslach Burnout Inventory (MBI) and Mini-Z surveys.
II. To explore any changes in the self-reported health status of participants, as measured by the RAND Short-Form 36 (SF36) survey.
III. To understand participants' perception of the benefits and usefulness of the intervention, measured by the customized Globalized Perception/Impression of Benefits Survey.
IV. To define methods for improving the intervention, based on participants' feedback following each session.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM A: Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
ARM B: Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks.
- Being tested
- Communication Intervention, Questionnaire Administration, Waiting List
- Medical subject headings
- Hematologic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Communication InterventionOther
Receive ECHO telementoring intervention
Questionnaire AdministrationOther
Ancillary studies
Waiting ListOther
Also called Waitlist
Placed on wait-list
| Study group | Role | What they receive |
|---|---|---|
| Arm A (ECHO telementoring) | Experimental | Participants attend ECHO telementoring sessions over 1 hour weekly for 13 weeks. Receives: Other: Communication Intervention; Other: Questionnaire Administration |
| Arm B (wait-list, ECHO telementoring) | Experimental | Participants are placed on a wait-list for 13 weeks and then attend ECHO telementoring sessions over 1 hour weekly for 13 weeks. Receives: Other: Communication Intervention; Other: Questionnaire Administration; Other: Waiting List |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of sessions attended
Will be evaluated by attendance records for each session. Will estimate the attendance rate (p = proportion of participants attending at least 9 out of 13 sessions) with 95% confidence intervals.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2019
- Study start16 Aug 2020
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematopoietic and Lymphoid Cell NeoplasmStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 36 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Eduardo Bruera, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04196972
- Sponsor's protocol ID
- 2019-0639
- Other IDs
- NCI-2019-07565, 2019-0639
- Status last verified
- Oct 2026
- First submitted
- 2 Dec 2019
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No